Saint Sean 4/A

What Happened Saint Sean, President & CEO (and director) of Beta Bionics, was granted a derivative award on 2026-02-27 covering 287,944 shares. The grant is reported as an award/acquisition (code A) at $0.00 per share (i.e., an option/award rather than a cash purchase). The Form 4 was amended (filed 2026-03-13) to correct the number of shares reported in the original Form 4 filed on 2026-03-03.

Key Details

• Transaction date: 2026-02-27; amended Form 4 filed 2026-03-13 (original filed 2026-03-03). Amendment corrects the reported share count.
• Transaction type/price: Award/Grant (derivative) — 287,944 shares; reported price $0.00.
• Vesting: Footnote F1 — vests in 36 equal monthly installments measured from March 1, 2026.
• Shares owned after transaction: Not specified in the information provided in this summary.
• No exercise or sale occurred at the time of this filing; this is a compensation award that vests over time.

Context This was a time-based option/award grant, not an immediate purchase or sale. That means no shares were sold and no cash was exchanged at grant; the award creates a right to future shares as they vest. Such awards are common executive compensation; they can lead to future dilution as options vest and (if exercised) shares are issued. The amendment improves accuracy of insider reporting, which is important for investors tracking insider activity.